In Vivo MicroCT Scanner

体内 MicroCT 扫描仪

• 批准号: 7797486
• 负责人: ROBERTO PACIFICI
• 金额: $ 49.35万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-06-15 至 2011-06-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7797486
• 关键词: 1-Phosphatidylinositol 3-Kinase; Acquired Immunodeficiency Syndrome; Animals; Bone Diseases; Brain Neoplasms; Charge; Collaborations; Complement; Data; Estrogens; Funding; Grant; HIV; Hand; Image; In Vitro; Life; Maintenance; Malignant Neoplasms; Measurement; Metastatic Neoplasm to the Bone; Methods; Minor; Modeling; Mus; Organ; Osteogenesis; Osteoporosis; Pharmaceutical Preparations; Research; Research Personnel; Role; Running; Sample Size; Savings; Scanning; Structure; T-Lymphocyte; TNF gene; TNFRSF5 gene; Training; Universities; bone; heart function; improved; in vivo; indexing; instrument; interest; kinase inhibitor; nanoparticle; oncology; operation; programs; public health relevance; tumor growth; 1-Phosphatidylinositol 3-Kinase; Acquired Immunodeficiency Syndrome; Animals; Bone Diseases; Brain Neoplasms; Charge; Collaborations; Complement; Data; Estrogens; Funding; Grant; HIV; Hand; Image; In Vitro; Life; Maintenance; Malignant Neoplasms; Measurement; Metastatic Neoplasm to the Bone; Methods; Minor; Modeling; Mus; Organ; Osteogenesis; Osteoporosis; Pharmaceutical Preparations; Research; Research Personnel; Role; Running; Sample Size; Savings; Scanning; Structure; T-Lymphocyte; TNF gene; TNFRSF5 gene; Training; Universities; bone; heart function; improved; in vivo; indexing; instrument; interest; kinase inhibitor; nanoparticle; oncology; operation; programs; public health relevance; tumor growth

DESCRIPTION (provided by applicant): We request funds to purchase a Scanco viva MicroCT model 40, a devise which makes it possible to scan live small animals with the purpose of imaging organs, evaluate heart function, quantify trabecular and cortical bone and obtain information about bone structure. It also allows rapid and accurate measurements of histomorphometric indices of bone volume, connectivity and structure. This instrument will be utilized by 7 major users [Drs. R. Pacifici (P.I.), G. Beck, L.W.K. Chung, M.S. Nanes, Dr. H. Shim M.N. Weitzmann, W. Lewis, who are PI for 7 RO-1s and 1 P0-1, 1 P20, 1 P50 and 1 VA merit grant, and run research programs, on bone, HIV- AIDS, nanoparticles, and cancer at Emory University. In addition, there will be 2 minor users, Drs. D. Durden, and M. Goodman who are P1 of 1 ro1, 1 P50 and a R56 grants, and have interests in oncology. Dr. Robert Guldberg, a collaborator of the P.I. and an expert on MicroCT will be in charge of the maintenance and operations of the instrument. Dr. Pacifici will utilize microCT in studies on the role of T cells in the mechanism of action of PTH and estrogen. Dr. Chung will utilize the microCT to study bone metastasis, Dr. Nanes will use microCT to determine the mechanism by which TNF blocks bone formation. Dr. Shim will utilize the microCT to visualize tumor growth, Dr. Beck and Weitzmann will be aided in their studies on the effects of nanoparticles in bone. Dr. Lewis will use microCT to assess heart function in mice treated with HIV drugs. Dr. Durden will study the effects of PI-3 kinase inhibitors on brain tumors. Dr. Goodman will utilize the microCT to visualize brain tumors. In vivo MicroCT will facilitate each of these projects as it will complement and/or substitute in vitro microCT and bone histomorphometry, and 2D echo for heart function analysis. The advantages of having a microCT are several. 1) It would make possible to expand the planned studies with in vivo data about bone structure, a capability which is currently not on hand. 2) The greater sensitivity and precision of microCT over other methods would results in increased group separation and thus increased ability to interpret the data in a conclusive manner. 3) In some cases it may be possible to decrease the duration of the studies or the sample size with considerable financial savings. 4) We would be able to conduct our studies at a much faster pace. 5) The increased capability of in vivo microCT would provide additional opportunity for collaborations, training of new investigators and opening new fields of research. PUBLIC HEALTH RELEVANCE: Access to an in vivo microCT would allow researchers into causes and cures for osteoporosis and other bone disorders, to expand their studies with data about bone structure from live animals, gain access to greater sensitivity and precision which would results in increased group separation and conclusive interpretation, decrease the duration of studies or the sample size with considerable financial savings, improve the ability to conduct studies at a much faster pace, add additional opportunity for collaborations and training of new investigators which may open new fields of research.

描述（由申请人提供）：我们要求资金购买Scanco Viva Microct Model 40，这是一种设计，这使得可以扫描具有成像器官的目的，评估心脏功能，量化小梁和皮质骨骼并获得有关骨骼结构的信息成为可能。它还可以快速准确地测量骨骼体积，连通性和结构的组织形态指标。该乐器将由7个主要用户使用[Drs。 R. Pacifici（P.I.），G。Beck，L.W.K。 Chung，M.S。 Nanes，H。ShimM.N.博士Weitzmann，W。Lewis，他的PI为7 RO-1S，1 P0-1、1 P20、1 P50和1 VA功绩授予，并在埃默里大学（Emory University）进行有关骨骼，艾滋病，纳米颗粒和癌症的研究计划。此外，DRS将有2个次要用户。 D. Durden和M. Goodman是1 RO1的P1，1 P50和R56赠款，并对肿瘤学具有兴趣。 P.I.合作者Robert Guldberg博士Microct专家将负责该工具的维护和操作。 Pacifici博士将在T细胞在PTH和雌激素作用机理中的作用研究中利用Microct。 Chung博士将利用Microct研究骨转移，Nanes博士将使用Microct来确定TNF阻断骨形成的机制。 Shim博士将利用Microct可视化肿瘤生长，贝克博士和魏茨曼博士将在他们对纳米颗粒在骨骼中的影响的研究中得到帮助。刘易斯博士将使用Microct评估用HIV药物治疗的小鼠的心脏功能。 Durden博士将研究PI-3激酶抑制剂对脑肿瘤的影响。古德曼博士将利用Microct可视化脑肿瘤。体内MicroCT将促进这些项目中的每个项目，因为它将补充和/或替代体外微观和骨骼组态图，以及2D回声进行心脏功能分析。具有微观的优势是几个。 1）可以通过有关骨结构的体内数据扩展计划的研究，这是目前尚未在场的能力。 2）与其他方法相比，MicroCT的更高敏感性和精度将导致组分离增加，从而提高以结论性的方式解释数据的能力。 3）在某些情况下，有可能减少研究持续时间或大量经济节省的样本量。 4）我们将能够以更快的速度进行研究。 5）体内Microct的能力提高将为合作，培训新研究人员和开放新的研究领域提供更多机会。 公共卫生相关性：获得体内微观的机会将使研究人员陷入骨质疏松症和其他骨骼疾病的原因和治疗方法，以扩大有关骨骼结构的研究，从活体动物中扩展研究，获得更大的敏感性和精确性，从而导致群体分离和结论性的培训增加，以减少研究的更多培训，以提高研究的持续时间，并增加了经济范围，并增加了经济范围，并增加了范围，并增加了范围的能力，并且能力促进了一项范围，并且能力促进了一项范围，并且能力促进了一项范围，并且能力促进了一项范围，并且能够促进一项范围，并且能够促进一项范围，并增加了一项范围，并且能够促进一项能力，并且能够促进一项能力，并且能够促进一项能力，并且能够促进parte ot的范围。可能开放新研究领域的新调查人员。